Russell Investments Group
HRTX icon

Russell Investments Group’s Heron Therapeutics HRTX Stock Holding History

Russell Investments Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.7K Buy
81,246
+68,575
+541% +$55K ﹤0.01% 3704
2026
Q1 		$10.1K Hold
12,671
– – ﹤0.01% 3789
2025
Q4 		$16.5K Sell
12,671
-4,547
-26% -$5.61K ﹤0.01% 3680
2025
Q3 		$21.7K Sell
17,218
-3,338
-16% -$5.29K ﹤0.01% 3571
2025
Q2 		$42.5K Buy
+20,556
New +$42K ﹤0.01% 3019
2024
Q4 		– Sell
-307
Closed -$611 – 3741
2024
Q3 		$611 Sell
307
-20
-6% -$48 ﹤0.01% 3545
2024
Q2 		$1.15K Buy
+327
New +$1K ﹤0.01% 3417
2023
Q4 		– Sell
-200
Closed -$206 – 3247
2023
Q3 		$206 Buy
+200
New +$285 ﹤0.01% 3493
2022
Q1 		– Sell
-4,302
Closed -$39K – 2829
2021
Q4 		$39K Buy
+4,302
New +$43.9K ﹤0.01% 2917
2021
Q3 		– Sell
-129,458
Closed -$2.01M – 3115
2021
Q2 		$2.01M Sell
129,458
-54,283
-30% -$864K ﹤0.01% 1920
2021
Q1 		$2.98M Buy
183,741
+5,265
+3% +$93.9K 0.01% 1647
2020
Q4 		$3.78M Buy
178,476
+64,284
+56% +$1.12M 0.01% 1397
2020
Q3 		$1.69M Sell
114,192
-8,303
-7% -$130K ﹤0.01% 1791
2020
Q2 		$1.8M Buy
122,495
+28,701
+31% +$472K ﹤0.01% 1698
2020
Q1 		$1.1M Sell
93,794
-11,333
-11% -$213K ﹤0.01% 1794
2019
Q4 		$2.47M Buy
105,127
+40,797
+63% +$903K ﹤0.01% 1613
2019
Q3 		$1.19M Buy
64,330
+19,342
+43% +$356K ﹤0.01% 1925
2019
Q2 		$836K Hold
44,988
– – ﹤0.01% 2059
2019
Q1 		$1.1M Buy
44,988
+3,337
+8% +$87.4K ﹤0.01% 2014
2018
Q4 		$1.08M Sell
41,651
-7,645
-16% -$210K ﹤0.01% 1907
2018
Q3 		$1.56M Sell
49,296
-1,600
-3% -$59.6K ﹤0.01% 1877
2018
Q2 		$1.98M Buy
50,896
+1,116
+2% +$35.5K ﹤0.01% 1761
2018
Q1 		$1.37M Buy
+49,780
New +$1.13M ﹤0.01% 2048
2017
Q2 		– Sell
-35,506
Closed -$532K – 2989
2017
Q1 		$532K Buy
+35,506
New +$491K ﹤0.01% 2402

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Russell Investments Group's HRTX Position: Q2 2026 in Review

Russell Investments Group increased its Heron Therapeutics (HRTX) stake by 541% in Q2 2026, buying an estimated $55K and bringing the position to 81,246 shares worth $34.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3704.

Russell Investments Group first reported a position in HRTX in Q1 2017 and has held it in 24 quarters since. The position peaked at $3.78M in Q4 2020. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Russell Investments Group held 81,246 shares of Heron Therapeutics worth $34.7K as of Q2 2026.
  • Russell Investments Group bought 68,575 Heron Therapeutics shares in Q2 2026, an estimated $55K.
  • Heron Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3704 holding.
  • Russell Investments Group first reported a position in Heron Therapeutics in Q1 2017 and has held it in 24 quarters since.
  • Russell Investments Group's Heron Therapeutics position peaked at $3.78M in Q4 2020.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.